Treatment approaches to juvenile dermatomyositis

Bibliography

• LAXER RM, FELDMAN BM: General and local scleroderma in children and dermatomyositis and associated syndromes. Carr: Opin. Rheumatol (1997) 9:458–464.
   PubMedGoogle Scholar
• KAIPIAINEN-SEPPANEN O, SAVOLAINEN A: Incidence of chronic juvenile rheumatic diseases in Finland during (1980-1990). Gin. Exp. Rheumatol (1996) 14:441–444.
   PubMed Web of Science ®Google Scholar
• SYMMONS DPM, SILLS JA, DAVIS SM: The incidence of juvenile Dermatomyositis: results from a nation-wide study. Br. J. Rheumatol (1995) 34:732–736.
   PubMedGoogle Scholar
• CASSIDY JT, PETTY RE: Juvenile Dermatomyositis. In: Textbook of pediatric rheumatology (4th edit" Cassidy JT, Petty RE (Eds), Churchill Livingstone, Edinburgh, UK (2000):465–504.
   Google Scholar
• PACHMAN LM, HAYFORD JR, CHUNG A et al.: Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J. Rheumatol (1998) 25(6):1198–1204.
   PubMed Web of Science ®Google Scholar
• ••A prospective study chronicling thefeatures at diagnosis in JDM.
   Google Scholar
• PELORO TM, MILLER OM, HAHN TF, NEWMAN ED: Juvenile dermatomyositis: A retrospective review of a 30-year experience. J. Am. Acad. Dermatol (2001) 45:28–34.
   PubMed Web of Science ®Google Scholar
• HIKETA T, OHASHI M: Juvenile dermatomyositis-statistical observation of 105 patients with dermatomyositis. Nippon Hifuka Cakkai Zasshi (1991) 101(8)825–830.
   Google Scholar
• SHEHATA R, AL-MAYOUF S, AL-DALAAN A, AL-MAZAID A, AL-BALAA S, BAHABRI S: Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin. Exp. Rheumatol (1999) 17(1):115–118.
   PubMed Web of Science ®Google Scholar
• ANSELL BM: Juvenile Dermatomyositis. Rheumatol (1992) 19\(Suppl. 33):60–62.
   Google Scholar
• BOHAN A, PETER JB: Polymyositis and dermatomyositis (1st part). N Engl. I Med. (1975) 292(7):344–347.
   PubMed Web of Science ®Google Scholar
• BOHAN A, PETER JB: Polymyositis and dermatomyositis (2nd part). N Engl. I Med. (1975) 292(8):403–407.
   PubMed Web of Science ®Google Scholar
• HANSON V: Dermatomyositis, scleroderma and polyarteritis nodosa. Clin. Rheum. Dis. (1976) 2:445–467.
   Google Scholar
• SULLIVAN DB, CASSIDY JT, PETTY RE:Dermatomyositis in the pediatric patient. Arthritic Rheum. (1977) 20:327–331.
   PubMedGoogle Scholar
• SPENCER CH, HANSON V, SINGSEN BH, BERNSTEIN BH, KORNREICH HK, KING KK: Course of treated juvenile dermatomyositis. Pediatr. (1984) 105:399–408.
   Web of Science ®Google Scholar
• TAIEB A, GUICHARD C, SALAMON R, MALEVILLE J: Prognosis of juvenile dermatomyositis. Pediatr. Dermatol (1985) 2:275–281.
   PubMedGoogle Scholar
• HUBER AM, LANG B, LEBLANC CM et al.: Medium and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritic Rheum. (2000) 43(3):541–549.
   PubMed Web of Science ®Google Scholar
• •A multi-centre, retrospective study on the long-term outcomes of children with JDM.
   Google Scholar
• CAWKWELL GMD: Juvenile dermatomyositis and polymyositis: a survey of current practices in North America. Rheumatol (2000) 27\(Suppl. 58):84.
   Google Scholar
• CAWKWELL GMD: Inflammatory myositis in children, including differential diagnosis. Carr: Opin. Rheumatol (2000) 12:430–434.
   PubMed Web of Science ®Google Scholar
• COHEN BH, SEDWICK LA, BURDE RM: Retinopathy of dermatomyositis.Neuroopthalmol(1985) 5:177–179.
   Web of Science ®Google Scholar
• TSE S, LUBERSKI S, GORDON M et al: The arthritis of inflammatory childhood myositis syndromes. J. Rheumatol (2001) 28:192–197.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DB, CASSIDY JT, PETTY RE, BURT A: Prognosis in childhood dermatomyositis. Pediatr. (1972) 80:555–563.
   Web of Science ®Google Scholar
• PEREZ MD, ABRAMS SA, KOENING G, STUFF JE, O'BRIEN KO, ELLIS KJ: Mineral metabolism in children with dermatomyositis. Rheumatol (1994) 21:2364–2369.
   Web of Science ®Google Scholar
• GOLDFIEN A: Adrenocorticosteroids and adrenocortical antagonists. In: Basic and Ounce] Pharmacology f7h edn" Katzung BG (Ed.), Appleton and Lange, Stamford, Connecticut, USA (1998):635–652.
   Google Scholar
• PACHMAN LM: Inflammatory myopathy in children. Rheum. Dis. Clin. North Am. (1994) 20:919–942.
   PubMed Web of Science ®Google Scholar
• RIDER LG, MILLER FW: Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. (1997) 23:619–655.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA T, SUEISHI M, NAWATA Y et al.: Methylprednisolone pulse therapy in dermatomyositis. Dermatologica (1983) 167:47–51.
   PubMedGoogle Scholar
• LAXER RM, STEIN LD, PETTY RE: Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum. (1987) 30:328–334.
   PubMed Web of Science ®Google Scholar
• HUANG JL: Long-term prognosis of patient with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Gin. Exp. Rheumatol (1999) 17:621–624.
   PubMed Web of Science ®Google Scholar
• LANG B, DOOLEY J: Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. Pediatr. (1996) 128:429–432.
   Web of Science ®Google Scholar
• PACHMAN LM, CALLEN AM, HAYFORD J et al.: Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arthritis Rheum. (1994) 37(Suppl.):429.
   Google Scholar
• ROMICKA AM: [Use of intravenous megadoses of methylprednisolone for treatment of dermatomyositis in children]. Pediatr. Pol. (1995) 70:243–248.
   PubMedGoogle Scholar
• CLARKE AE, BLOCH DA, MEDSGER TA Jr, ODDIS CV: A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum. (1995) 38:1218–1224.
   PubMed Web of Science ®Google Scholar
• VILLALBA L, ADAMS EM: Update on therapy for refractory dermatomyositis and polymyositis. Carr. Opin. Rheumatol (1996) 8:544–551.
   PubMedGoogle Scholar
• WOO TY, CALLEN JP, VOORHEES JJ, BICKERS DR, HANNO R, HAWKINS C: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. I Am. Acad. Dermatol (1984) 10:592–600.
   PubMed Web of Science ®Google Scholar
• OLSON NY, LINDSLEY CB: Adjunctive use of hydroxychloroquine in childhood dermatomyositis. Rheumatol (1989) 16:1545–1547.
   Web of Science ®Google Scholar
• MALAVIYA A, MANY A, SCHWARTZ R:Treatment of dermatomyositis with methotrexate. Lancet (1968) 2:485–488.
   PubMed Web of Science ®Google Scholar
• HILL R, WOOD W: Juvenile dermatomyositis. Can. Med. Assoc. J. (1970) 103:1152–1156.
   PubMed Web of Science ®Google Scholar
• ARNETT F, WHELTON J, ZIZIC T, STEVENS M: Methotrexate therapy in polymyositis. Ann. Rheum. Dis. (1973) 32:536–546.
   PubMed Web of Science ®Google Scholar
• METZGER A, BOHAN A, GOLDBERG L, BLUESTONE R, PEARSON C: Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann. Intern. Med. (1981) 81:182–189.
   Google Scholar
• JACOBS J: Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics (1977) 59:212–218.
   PubMed Web of Science ®Google Scholar
• NIAKAN E, PITNER S, WHITAKER J,BERTORINI T: Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology (1980) 30:286–291.
   PubMed Web of Science ®Google Scholar
• FISCHER T, RACHELEFSKY G, KLEIN R, PAULUS H, STIEHM E: Childhood dermatomyositis and polymyositis: treatment with methotrexate and prednisolone. Am. J. Dis. Child (1979) 133:386–389.
   PubMedGoogle Scholar
• MILLER LC, SISSON BA, TUCKER LB, DENARDO BA, SCHALLER JG: Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritic Rheum. (1992) 35(10):1143–1149.
   PubMed Web of Science ®Google Scholar
• AL-MAYOUF S, AL-MAZIAD A, AL-DALAAN A et al.: Severe juvenile dermatomyositis: efficacy of early treatment with methotrexate. Rheumatol (2000) 27\(Suppl. 58):84.
   Google Scholar
• CHABNER B, ALLEGRA C, CURT G et al.: Polyglutamation of methotrexate. .1 Clin. Invest. (1985) 76:907–912.
   Google Scholar
• ROSE C, SINGSEN B, EICHENFIELD A, GOLDSMITH D, ATHREYA B: Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J. Pediatr. (1990) 117:653–659.
   PubMed Web of Science ®Google Scholar
• GRAHAM L, MYONES B, RIVAS-CHACON R, PACHMAN L: Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J. Pediatr. (1992) 120:468–473.
   PubMed Web of Science ®Google Scholar
• GIANNINI E, BREWER E, KUZMINA Net al.: Methotrexate in resistant juvenile rheumatoid arthritis. N Engl." Med. (1992) 326:1043–1049.
   Google Scholar
• EISLER RE, LIANG MG, FUHLBRIGGE RC, YALCINDAG A, SUNDEL RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. Am. Acad. Dermatoi (2002) 47(4):505–511.
   PubMed Web of Science ®Google Scholar
• RAMANAN AV, CAMPBELL-WEBSTER N, TRAN D et al: Initial managemnt of juvenile dermatomyositis using methotrexate and aggressively tapered prednisone. Pediatric Rheumatology Online Journal (2002) 1(4):124.
   Google Scholar
• LANG BA, LAXER RIVI, MURPHY G, SILVERMAN ED, ROIFMAN CM: Treatment of dermatomyositis with intravenous gammaglobulin. Arn. J. Med. (1991) 91:169–172.
   Google Scholar
• COLLET E, DALAC S, MAERENS B, COURTOIS JM, IZAC M, LAMBERT D: Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br. .1 Dermatol (1994) 130:231–234.
   Google Scholar
• ROIFMAN CM: Use of intravenous immune globulin in the therapy of children with rheumatological diseases. Clin. Immunol (1995) 15:42S–51S.
   Google Scholar
• SANSOME A, DUBOWITZ V: Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch. Dis. Child. (1995) 72:25–28.
   PubMed Web of Science ®Google Scholar
• TSAI MJ, LAI CC, LIN SC, CHIANG BL, CHOU CC, HSIEH KH: Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Ke Yi Xue Hui Za Zhi (1997) 38:111–115.
   PubMedGoogle Scholar
• AL-MAYOUF SM, LAXER RIVI, SCHNEIDER R, SILVERMAN ED, FELDMAN BM: Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. Rheumatol (2000) 27:2498–2503.
   Web of Science ®Google Scholar
• CHERIN P, HERSON S, WECHSLER Bet al.: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am. Med. (1991) 91:162–168.
   Google Scholar
• CHERIN P, PIETTE JC, WECHSLER Bet al.: Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. Rheumatol. (1994) 21:1092–1097.
   Google Scholar
• DALAKAS MC, ILLA I, DAMBROSIA JM et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl. J. Med. (1993) 329:1993–2000.
   PubMed Web of Science ®Google Scholar
• ••A randomised, controlled trial ofimmunoglobulins in adult dermatomyositis.
   Google Scholar
• KATO E, SHINDO S, ETO Y et al: Administration of immune globulin associated with aseptic meningitis. JAMA (1988) 259:3269–3271.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH A, FELDMAN B, SINGH Get al.: Aseptic meningitis following intravenous immune globulin in children. Arthritic Rheum. (1991) 34:S121.
   Google Scholar
• JACOBS JC: Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics (1977) 59:212–218.
   PubMed Web of Science ®Google Scholar
• BENSON MD, ALDO MA: Azathioprine therapy in polymyositis. Arch. Intern. Med. (1973):447–451.
   PubMedGoogle Scholar
• CROWE WE, BOVE KE, LEVINSON JE, HILTON PK: Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthitis Rheum. (1982):126–139.
   PubMed Web of Science ®Google Scholar
• CRONIN ME, MILLER FW, HICKS JE, DALAKAS M, PLOTZ PH: The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. Rheumatol (1989) 16:1225–1228.
   Web of Science ®Google Scholar
• NAKASHIMA S, MORI M, MIYAMAE T et al.: Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis. Ry4umachi (2002) 42 (6):895–902.
   Google Scholar
• ZABEL P, LEIMENSTOLL G, GROSS WL: Cyclosporin for acute dermatomyositis. Lancet (1984) 1:343.
   PubMed Web of Science ®Google Scholar
• GIRARDIN E, DAYERJM, PAUNIER L: Cyclosporine for juvenile dermatomyositis. Pediatr. (1988) 112:165–166.
   Web of Science ®Google Scholar
• HECKMATT J, HASSON N, SAUNDERS C et al: Cyclosporin in juvenile dermatomyositis. Lancet (1989) 1:1063–1066.
   PubMed Web of Science ®Google Scholar
• DANTZIG P: Juvenile dermatomyositis treated with cyclosporine. J Am. Acad. Dermatol (1990) 22:310–311.
   PubMed Web of Science ®Google Scholar
• ZELLER V, COHEN P, PRIEUR AM, GUILLEVIN L: Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and long-term follow-up of 6 cases. Rheumatol (1996) 23:1424–1427.
   Google Scholar
• REIFF A, RAWLINGS DJ, SHAHAM B et al.: Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile arthritis and juvenile dermatomyositis. Rheumatol. (1997) 24:2436–2443.
   Web of Science ®Google Scholar
• GRAU JM, HERRERO C, CASADEMONT J, FERNANDEZ-SOLA J, URBANO-MARQUEZ A: Cyclosporine A as first choice therapy for dermatomyositis. j Rheumatol (1994):381–382.
   PubMed Web of Science ®Google Scholar
• PETERS AM, HECKMATT JZ, HASSON N et al: Renal haemodynamics of cyclosporin A nephrotoxicity in children with juvenile dermatomyositis. Clin. Sci. (Iond) (1991) 81:153–159.
   PubMed Web of Science ®Google Scholar
• OSTENSEN M, HOYERAAL HM, KASS E: Tolerance of cyclosporine A in children with refractory juvenile chronic arthritis. J. Rheumatol (1988) 15:1536–1538.
   PubMed Web of Science ®Google Scholar
• PISTOIA V, BUONCOMPAGNI A, SCRIBANIS R et al.: Cyclosporine A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin. Exp. Rheumatol (1992) 11:203–208.
   Web of Science ®Google Scholar
• MUKAMEL M, HOREV G, MIMOUNI M: New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. Pediatr. (2001) 138:763–766.
   Web of Science ®Google Scholar
• HERD JK, VAUGHAN JH: Calcinosis universalis complicating dermatomyositis: its treatment with Na2EDTA. Report of two cases in children. Arthritis Rheum. (1964) 7:259.
   PubMed Web of Science ®Google Scholar
• NASSIM JR, CONNOLLY CK: Treatment of calcinosis universalis with aluminium hydroxide. Arch. Dis. Child. (1970) 45:118–121.
   PubMed Web of Science ®Google Scholar
• DENT CE, STAMP TC: Treatment of calcinosis circumscripta with probenecid. Br. Med. J. (1972) 1:216–218.
   PubMed Web of Science ®Google Scholar
• METZGER AL, SINGER FR, BLUESTONE R, PEARSON CM: Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N Engl. J. Med. (1974) 291:1294–1296.
   PubMed Web of Science ®Google Scholar
• TABORN J, BOLE GG, THOMPSON GR: Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann. Intern. Med. (1978) 89:648–649.
   PubMed Web of Science ®Google Scholar
• MILLER G, HECKMATT JZ, DUBOWITZ V: Drug treatment of juvenile dermatomyositis. Arch. Dis. Child. (1983) 58:445–450.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-CORDERO E, LOPEZ-ZEPEDAJ, CHOZA-ROMERO F: Calcinosis in childhood dermatomyositis. Clin. Exp. Rheumatol (1990):198–200.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA T, TAKAIWA T: Calcinosis cutis in juvenile dermatomyositis responsive to aluminium hydroxide treatment. Dermatol (1993) 20:558–560.
   Google Scholar
• OLIVERI MB, PALERMO R, MAUTALEN C, HUBSCHER O: Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. Rheumatol (1996) 23(12):2152–2155.
   Web of Science ®Google Scholar
• EDDY MC, LEELAWATTANA R, MCALISTER WH, WHYTE MP: Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. j. Clin. Endocrinol Metab. (1997) 82(11):3536–3542.
   PubMed Web of Science ®Google Scholar
• HAREL L, HAREL G, KORENREIGH L, STRAUSSBERG R, AMIR J: Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J. Rheumatol (2001) 28(5):1129–1132.
   PubMed Web of Science ®Google Scholar
• TAUSCHE A, MEURER M: Mycohenolate mofetil for dermatomyositis. Dermatol (2001) 202:341–343.
   PubMed Web of Science ®Google Scholar
• HOLLAR C, JORIZZO J: Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J. Dermatol Treat. (2004) 15(1):35–39.
   Google Scholar
• YOSHIMASU T, OHTANI T, SAKAMOTO T, OSHIMA A, FURUKAWA F: Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eurj Dermatol (2002) 12(1):50–52.
   PubMed Web of Science ®Google Scholar
• UEDA M, MAKINODAN R, MATSUMURA M, ICHIHASHI M: Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br: J. Dermatol (2003) 148(3):595–596.
   PubMed Web of Science ®Google Scholar
• TUTUNCU Z, MORGAN GJ Jr, KAVANAUGH A: Anti-TNF therapy for other inflammatory conditions. Clin. Exp. Rheumatol (2002) 20(6):5146–5151.
   Web of Science ®Google Scholar
• MILLER M, MENDEZ E, KLEIN-GITELMAN MS, PACHMAN LM: Experience with etarnecept in chronic juvenile dermatomyositis: preliminary results. American College of Rheumatology 64th Annual Scientific Meeting, Philadelphia, USA, poster session, board number: 293 (2000).
   Google Scholar
• SHIMIZU T, TOMITA Y, SON K, NISHINARITA S, SAWADA S: Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin. Rheumatol (2000) 19(5):352–359.
   PubMed Web of Science ®Google Scholar
• RAMANAN AV, FELDMAN BM: Clinical features and outcomes of juvenile dermatomyositis and other childhood myositis syndromes. Rheum. Dis. Clin. North Am. (2002) 28(4):833–857.
   PubMed Web of Science ®Google Scholar
• HOOGENDIJK JE, AMATO AA, LECKY BR et al.: 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. (2004) 14(5):337–345.
   PubMedGoogle Scholar
• ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology(2004) 43:49–54.
   Google Scholar
• PEREZ MD, ABRAMS SA, KOENNING G, STUFF JE, O'BRIEN KO, ELLIS KJ: Mineral metabolism in children with dermatomyositis. Rheumatol (1994) 21:2364–2369.
   Web of Science ®Google Scholar
• FISLER RE, LIANG MG, FUHLBRIGGE RC, YALCINDAG A, SUNDEL RP: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J. Am. Acad. Dermatol (2002) 47(0505–511.
   PubMed Web of Science ®Google Scholar